Erlonat® 150
Brand Name: Erlonat® 150
Composition: Erlotinib Tablets I.P. (150 mg)
Quantity: 30 Tablets
Manufacturer: NATCO
Product Description
Medical Info
Erlonat® 150 is a specialized oncological medication containing 150 mg of Erlotinib, manufactured under strict quality standards by NATCO. As a potent tyrosine kinase inhibitor, it specifically targets the Epidermal Growth Factor Receptor (EGFR) pathways. It is clinically indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations, as well as in combination regimens for advanced-stage pancreatic cancer. Each pack contains 30 tablets designed to deliver precise therapeutic management. By blocking signals that stimulate cancer cells to proliferate, Erlonat® 150 provides a critical targeted treatment option in modern oncology.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
